| Code | CSB-RA015511MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of lorvotuzumab mertansine (IMGN901), targeting NCAM1 (also known as CD56), a neural cell adhesion molecule in the immunoglobulin superfamily that mediates cell–cell and cell–matrix interactions. NCAM1/CD56 is expressed on neural-lineage cells and has been reported as overexpressed in multiple malignancies, including neuroblastoma, small-cell lung cancer, multiple myeloma, and ovarian cancer, where it has been linked to tumor invasion and metastatic potential in certain contexts.
Lorvotuzumab mertansine is an antibody–drug conjugate (ADC) in which a humanized anti-CD56 (NCAM1) monoclonal antibody (lorvotuzumab/huN901) is conjugated to the maytansinoid microtubule inhibitor DM1 via a disulfide linker. This biosimilar provides the antibody component alone, enabling researchers to investigate NCAM1 antigen biology, cell-surface binding, and target-mediated internalization/trafficking mechanisms independently of DM1-driven cytotoxicity. It supports oncology and ADC-discovery workflows that require decoupling target engagement/internalization from payload effects when evaluating NCAM1/CD56 as a tumor-associated surface antigen.
There are currently no reviews for this product.